1.27
0.01 (0.79%)
| Penutupan Terdahulu | 1.26 |
| Buka | 1.29 |
| Jumlah Dagangan | 42,752 |
| Purata Dagangan (3B) | 2,517,746 |
| Modal Pasaran | 2,303,949 |
| Harga / Pendapatan (P/E TTM) | 0.008 |
| Harga / Jualan (P/S) | 54.99 |
| Harga / Buku (P/B) | 0.570 |
| Julat 52 Minggu |
| EPS Cair (TTM) | 277.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.17% |
| Nisbah Semasa (MRQ) | 2.71 |
| Aliran Tunai Operasi (OCF TTM) | -6.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.55 M |
| Pulangan Atas Aset (ROA TTM) | -80.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -200.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Bluejay Diagnostics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.17 |
|
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.26% |
| % Dimiliki oleh Institusi | 2.48% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Nov 2025 | Pengumuman | Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships |
| 10 Oct 2025 | Pengumuman | Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules |
| 09 Oct 2025 | Pengumuman | Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules |
| 09 Oct 2025 | Pengumuman | Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |